全部 标题 作者 关键词 摘要
DOI: 10.3971/j.issn.1000-8578.2019.18.0962
Keywords: A Predictor of Risk and Prognosis of Breast Cancer,Tanshinone ⅡA Enhances Chemosensitivity of Breast Cancer Cells to Doxorubicin and Related Mechanism,In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer,Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition,Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer,Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib,Influence of NRP-1 Monoclonal Antibody on Growth of Breast Cancer Xenografts in Nude Mouse,Expression of Circular RNA ciRS-7 and Its Effect on Invasion and Migration of Triplenegative reast Cancer Cells,Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
Full-Text Cite this paper Add to My Lib
摘要 目的 探讨不同HR状态的HER2阳性晚期乳腺癌患者的复发转移特征、预后及解救曲妥珠单抗治疗疗效的差异。方法 回顾性分析237名HER2阳性晚期乳腺癌患者的临床病理学资料，根据HR状态分为HR+/HER2+组和HR-/HER2+组，对两组间临床病理学特征、复发转移特点、预后及解救曲妥珠单抗治疗疗效进行分析比较。结果 与HR-/HER2+相比，HR+/HER2+多为绝经前患者，临床分期以Ⅰ~Ⅱ期为主，T分期更早，较少发生腋窝淋巴结转移。在总体复发转移部位上HR+/HER2+者更易发生骨转移，较少发生肺转移。HR+/HER2+组中位总生存时间34（5~102）月，HR-/HER2+组为29（3~70）月，两组间差异有统计学意义。接受解救曲妥珠单抗联合化疗的患者，ER<50%者达PR者占68.6%，ER≥50%者占46.2%，差异有统计学意义（P=0.037）。多因素分析结果显示ER状态是HR+/HER2+晚期乳腺癌的独立预后因素；肝转移、解救抗HER2靶向治疗是HR-/HER2+晚期乳腺癌的独立预后因素。结论 与HR-/HER2+患者相比，HR+/HER2+患者多发生骨转移，较少发生肺转移；预后较好；ER阳性细胞数所占比例较高的患者解救曲妥珠单抗治疗疗效较差
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
